CYTR News and Press, CytRx Corporation From 05/21/20

LOS ANGELES , May 21, 2020 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that ImmunityBio and NantKwest announced the initiation of a Phase 2...

LOS ANGELES , April 29, 2020 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that Orphazyme A/S (ORPH.CO) has provided updated information rega...

LOS ANGELES , March 10, 2020 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today announced that effective immediately, Mr. Eric Curtis , President and Chief Operat...

LOS ANGELES , Feb. 28, 2020 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today clarified certain prior disclosures regarding its relationship with Orphazyme A...

CytRx ( OTC:CYTR +127.1% ) announces positive results from a 24-subject  Phase 2 pilot study evaluating arimoclomol in patients with a rare progressive muscle disorder called sporadic inclusion body myositis characterized by inflammation, weakness and atrophy. More news on: Cyt...

LOS ANGELES , Feb. 11, 2020 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted Orphazyme's recently published data from its double-blinded Phase 2...

LOS ANGELES , Feb. 4, 2020 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that arimoclomol licensee Orphazyme A/S (ORPH.CO) has provided updat...

LOS ANGELES , Jan. 29, 2020 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company, today highlighted that ImmunityBio, previously NantCell, Inc., and NantKwest announced a complete response in Metastatic Pancreatic Cancer in one patient...

Thinly traded nano cap CytRx ( OTC:CYTR +1.9% ) perks up, albeit on turnover of only 19K shares, in response to accelerated review designations in the U.S. for arimoclomol, out-licensed to Orphazyme A/S in 2011. More news on: CytRx Corporation, Healthcare stocks news, Stocks on the mov...

LOS ANGELES , Dec. 19, 2019 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company, today highlighted Orphazyme A/S received FDA Breakthrough Therapy Designation for arimoclomol for NPC. Breakthrough Therapy Designation is a program inte...